A Phase II study evaluating tumour response of Cetuximab (ErbituxTM) plus weekly docetaxel chemotherapy in docetaxel refractory patients with advanced oesophago-gastric cancer.
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ATTAX-2
- 29 Dec 2009 New trial record